Generic opportunity for Alchemia
Friday, 13 March, 2009
Alchemia’s manufacturing partner Dr Reddy’s Laboratories has filed an abbreviated new drug application with the US FDA for a generic version of fondaparinux, used to prevent blood clots.
Fondaparinux is currently marketed by GlaxoSmithKline under the brand name Atrixa, which came off patent in 2002.
No other company has filed an application for a generic in that time as fondaparinux is a difficult molecule to synthesise, Alchemia said.
It is hoped the FDA will review the application within six months of filing under a priority review system.
Overuse of inhalers can increase heart attack risk
Overuse of reliever inhalers is associated with higher risks of developing and dying from...
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
